Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

8.82USD
24 Apr 2019
Change (% chg)

$-0.04 (-0.45%)
Prev Close
$8.86
Open
$8.85
Day's High
$8.94
Day's Low
$8.77
Volume
31,296
Avg. Vol
56,226
52-wk High
$15.75
52-wk Low
$8.06

Latest Key Developments (Source: Significant Developments)

Kindred Biosciences Announces Fourth Quarter And Full Year 2018 Financial Results
Wednesday, 6 Mar 2019 04:01pm EST 

March 6 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.QTRLY NET PRODUCT REVENUES $1.3 MILLION VERSUS NO PRODUCT REVENUES FOR THE SAME PERIOD LAST YEAR.  Full Article

Kindred Biosciences Says Public Offering Of 4.22 Mln Common Shares Priced At $9.50/Share
Friday, 18 Jan 2019 09:31am EST 

Jan 18 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 4.22 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.  Full Article

Kindred Biosciences Announces Q3 Loss Per Share $0.39
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.39.Q3 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.  Full Article

Kindred Biosciences Announces Positive Results From Pilot Effectiveness Study
Tuesday, 30 Oct 2018 04:01pm EDT 

Oct 30 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM PILOT EFFECTIVENESS STUDY OF ITS FULLY CANINIZED IL-31 ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS IN DOGS AND ISSUANCE OF U.S. PATENT.KINDRED BIOSCIENCES INC - STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS VERSUS PLACEBO WAS ACHIEVED ACROSS ALL DOSE GROUPS.KINDRED BIOSCIENCES INC - U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT (PATENT NO. 10,093,731) FOR KINDREDBIO'S ANTI-IL31 ANTIBODY.KINDRED BIOSCIENCES INC - BASED ON A PRELIMINARY REVIEW OF SAFETY DATA, IL-31 DRUG APPEARS TO BE WELL TOLERATED.  Full Article

Kindred Biosciences Announces Pricing Of Public Offering
Wednesday, 20 Jun 2018 09:10am EDT 

June 20 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 4.63 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.SAYS PUBLIC OFFERING OF 4.63 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.  Full Article

Kindred Biosciences Q4 Loss Per Share $0.35
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.35.  Full Article

KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz
Thursday, 21 Dec 2017 08:02am EST 

Dec 21 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™.KINDRED BIOSCIENCES INC - EMA HAS ACCEPTED SUBMISSION FOR REVIEW, WITH OFFICIAL ACCEPTANCE DATE OF DECEMBER 21, 2017.KINDRED BIOSCIENCES INC - EXECUTED NATIONAL DISTRIBUTION DEALS WITH MWI VETERINARY SUPPLY CO. & DIRECT VET MARKETING, INC. D/B/A VETS FIRST CHOICE.  Full Article

KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral
Monday, 4 Dec 2017 08:02am EST 

Dec 4 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES.KINDRED BIOSCIENCES INC - ‍BASED ON PRELIMINARY REVIEW OF SAFETY DATA, DRUG ZIMETA APPEARS TO BE WELL TOLERATED ​.KINDRED BIOSCIENCES INC - CO ANTICIPATES SUBMITTING EFFECTIVENESS TECHNICAL SECTION OF NEW ANIMAL DRUG APPLICATION IN EARLY 2018​.  Full Article

Kindred Biosciences posts Q3 loss of $0.29 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Kindred Biosciences Inc :Kindred biosciences announces third quarter 2017 financial results.Q3 loss per share $0.29.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Kindred Biosciences Q2 loss per share $0.29
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Kindred Biosciences Inc :Kindred Biosciences announces second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Kindred Biosciences - ‍for 2017 , reiterates its previous guidance for operating expenses to be in range of $30 million to $32 million, excluding items​.  Full Article